In today’s session Quest Diagnostics Inc (DGX) registered an unusually high (230) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the November, 2016 call, expecting serious DGX increase. With 230 contracts traded and 4534 open interest for the Nov, 16 contract, it seems this is a quite bullish bet. The option with symbol: DGX161118C00080000 closed last at: $5.5 or 161.9% up. About 141,904 shares traded hands. Quest Diagnostics Inc (NYSE:DGX) has risen 15.21% since April 14, 2016 and is uptrending. It has outperformed by 10.53% the S&P500.
Quest Diagnostics Inc (NYSE:DGX) Ratings Coverage
Out of 9 analysts covering Quest Diagnostics (NYSE:DGX), 2 rate it a “Buy”, 1 “Sell”, while 6 “Hold”. This means 22% are positive. Quest Diagnostics has been the topic of 16 analyst reports since August 4, 2015 according to StockzIntelligence Inc. The firm earned “Market Perform” rating on Friday, October 16 by Wells Fargo. The stock of Quest Diagnostics Inc (NYSE:DGX) has “Neutral” rating given on Wednesday, August 31 by Mizuho. On Friday, June 24 the stock rating was downgraded by Jyske Bank to “Sell”. On Friday, November 13 the stock rating was maintained by Canaccord Genuity with “Buy”. The firm earned “Hold” rating on Tuesday, August 18 by Zacks. The firm has “Neutral” rating by Mizuho given on Thursday, October 22. The stock of Quest Diagnostics Inc (NYSE:DGX) earned “Neutral” rating by Mizuho on Friday, October 21. RBC Capital Markets maintained it with “Sector Perform” rating and $70 target price in Friday, October 23 report. RBC Capital Markets maintained the stock with “Sector Perform” rating in Friday, January 29 report. On Monday, November 14 the stock rating was upgraded by UBS to “Buy”.
According to Zacks Investment Research, “Quest Diagnostics Inc., is the leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its national network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative new diagnostic tests and advanced healthcare information technology solutions that help improve patient care.”
Insitutional Activity: The institutional sentiment increased to 1.07 in 2016 Q2. Its up 0.02, from 1.05 in 2016Q1. The ratio improved, as 35 funds sold all Quest Diagnostics Inc shares owned while 173 reduced positions. 55 funds bought stakes while 168 increased positions. They now own 124.00 million shares or 7.05% less from 133.41 million shares in 2016Q1.
Cipher Cap Limited Partnership holds 0.04% of its portfolio in Quest Diagnostics Inc (NYSE:DGX) for 6,526 shares. Value Capital Ltd Limited Liability Company has invested 6.53% of its portfolio in Quest Diagnostics Inc (NYSE:DGX). Meag Munich Ergo Kapitalanlagegesellschaft Mbh, a Germany-based fund reported 2,000 shares. Investors has 3.28M shares for 0.39% of their US portfolio. Assetmark Inc holds 0% of its portfolio in Quest Diagnostics Inc (NYSE:DGX) for 455 shares. Creative Planning accumulated 1,972 shares or 0% of the stock. C M Bidwell & Limited reported 52,720 shares or 1.06% of all its holdings. Pinnacle Assocs Limited has invested 0.07% of its portfolio in Quest Diagnostics Inc (NYSE:DGX). Ig Invest Mgmt Limited has 0.04% invested in the company for 111,050 shares. Raymond James And Associates holds 0.14% of its portfolio in Quest Diagnostics Inc (NYSE:DGX) for 534,899 shares. Moreover, Wedge Capital Mngmt L L P Nc has 0.14% invested in Quest Diagnostics Inc (NYSE:DGX) for 579,537 shares. Wolverine Asset Management Lc has 0.01% invested in the company for 9,920 shares. Conning has invested 0.03% of its portfolio in Quest Diagnostics Inc (NYSE:DGX). Kbc Grp Nv has invested 0.05% of its portfolio in Quest Diagnostics Inc (NYSE:DGX). Covington holds 0.03% or 3,650 shares in its portfolio.
Insider Transactions: Since July 25, 2016, the stock had 0 buys, and 4 insider sales for $1.31 million net activity. Shares for $543,262 were sold by LEIDEN JEFFREY M on Wednesday, August 3. The insider ZIEGLER JOHN B sold $84,359. The insider BRITELL JENNE K sold $340,808.
Quest Diagnostics Incorporated is a well-known provider of diagnostic information services. The company has a market cap of $11.79 billion. The Firm operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. It has a 17.99 P/E ratio. The Company’s Diagnostic Information Services business develops and delivers diagnostic testing information and services to patients, physicians, health plans, hospitals, accountable care organizations , integrated delivery networks (IDNs), other commercial laboratories, employers and others.
DGX Company Profile
Quest Diagnostics Incorporated, incorporated on September 20, 1996, is a well-known provider of diagnostic information services. The Firm operates through two businesses: Diagnostic Information Services and Diagnostic Solutions.
More recent Quest Diagnostics Inc (NYSE:DGX) news were published by: Wsj.com which released: “Quest Diagnostics to Sell Focus Diagnostics to DiaSorin” on March 30, 2016. Also Wsj.com published the news titled: “UnitedHealth’s Optum Unit to Oversee Quest Diagnostics’ Billing Processes” on September 13, 2016. Forbes.com‘s news article titled: “Ex-Dividend Reminder: Sanderson Farms, Quest Diagnostics and Agilent Technologies” with publication date: September 28, 2016 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.